William Blair Has Positive Outlook for IONS Q1 Earnings
William Blair lifted their Q1 2026 earnings estimates for shares of Ionis Pharmaceuticals in a research note issued on ...
Zacks Investment Research on MSN2d
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired ...
Fierce Biotech2d
Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer
Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...
Pharmaceutical Technology on MSN2d
Ono earmarks $940m to gain rare blood cancer therapy from Ionis
Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...
Business Wire3d
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...
BioSpace2d
Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
Ionis Pharmaceuticals (IONS) Receives a Buy from William Blair
William Blair analyst Myles Minter reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today. The company’s shares opened ...
PMLive21h
AstraZeneca/Ionis’ Wainzua granted EC approval to treat rare disease ATTRv-PN
AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat ...
Ono pays $280M to license Ionis rare disease drug
Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...
Fierce Pharma21h
Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
Yahoo Finance3d
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical ...